Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies.
about
PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical applicationInhibition of the PI3K/Akt/mTOR signaling pathway in diffuse large B-cell lymphoma: current knowledge and clinical significanceThe Complexity of Targeting PI3K-Akt-mTOR Signalling in Human Acute Myeloid Leukaemia: The Importance of Leukemic Cell Heterogeneity, Neighbouring Mesenchymal Stem Cells and Immunocompetent CellsSevoflurane postconditioning protects rat hearts against ischemia-reperfusion injury via the activation of PI3K/AKT/mTOR signalingThe role of PI3K/Akt in human herpesvirus infection: From the bench to the bedsideInsulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance.Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian CancerImpact of mTOR expression on clinical outcome in paediatric patients with B-cell acute lymphoblastic leukaemia - preliminary reportc-Myc suppresses miR-451⊣YWTAZ/AKT axis via recruiting HDAC3 in acute myeloid leukemia.PI-3 kinase p110β: a therapeutic target in advanced prostate cancers.Control of B lymphocyte development and functions by the mTOR signaling pathways.Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation.Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes.Afatinib down-regulates MCL-1 expression through the PERK-eIF2α-ATF4 axis and leads to apoptosis in head and neck squamous cell carcinomaVerteporfin Inhibits Cell Proliferation and Induces Apoptosis in Human Leukemia NB4 Cells without Light Activation.Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia.B lymphoblastic leukemia/lymphoma: new insights into genetics, molecular aberrations, subclassification and targeted therapy.Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.Association between integrin-linked kinase and hyperthermia in oral squamous cell carcinoma.Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia (T-ALL).Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia.Development of highly sensitive cell-based AKT kinase ELISA for monitoring PI3K beta activity and compound efficacy.A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114).Novel strategies for targeting leukemia stem cells: sounding the death knell for blood cancer.Childhood relapsed acute lymphoblastic leukemia: Biology and recent treatment progress.SRC/ABL inhibition disrupts CRLF2-driven signaling to induce cell death in B-cell acute lymphoblastic leukemia.
P2860
Q26801538-B28F7817-254F-4858-B903-46BADA66C935Q26991637-25E25C33-A9A0-46A6-AF5A-77CEFB46324FQ28074203-DC1D7C7C-916A-44AE-8310-80161DFD333DQ34628699-80E19D4D-D5C2-4FE3-B755-410C4956AE2FQ35582498-18368B02-37CD-4350-80EA-F39118AD8FAEQ35606589-27A311C3-5AAF-417E-B76C-3710EB30DC9EQ36167088-1EBD19D1-BCEA-49AD-9394-151286C022A9Q37274340-36F9DA34-95AD-4147-8B2E-3026B1571DEAQ37718379-F690815C-25BC-4B1E-936E-C354293E64F2Q38265574-0708CB74-4FD9-4C59-A397-27B7E2962932Q38674507-CC39FBC3-01F5-4C9B-BC65-DD8D22B7E377Q38949674-B9244D7A-FE31-4660-BAD8-EBDDCE20488DQ39992854-C2BC0BC4-20B0-42EF-85C1-FB7400B84E14Q40970957-EEE21B24-F83E-45AB-9846-5BCA31A63F22Q41035347-2B226E5D-A660-4764-9F33-33CBADFA20E9Q41904096-C8FC7B96-5A85-4824-B737-DCB3B12D7FE7Q42317505-BA16ED1E-83AD-42BB-9D31-C16F3AC738E9Q42371687-DE81C776-7C3A-4163-9A6E-DCAFE76B2946Q42440865-55553F35-6902-4374-81C7-668785BDC611Q47106351-8BD9334D-9674-4A5B-90FC-412F6E52402BQ47203479-9DC94EC4-C0E3-40F8-B2F3-5628B92E06BBQ47754054-62AB8263-2881-4D47-B9AB-53599F895D97Q50073152-1EA6F16B-8026-45C9-91AD-4540499A7B80Q50799489-8324C418-289F-4824-A46E-D2CAA6B64E96Q52846906-B5F4F642-DC16-4377-B5E2-0736F855AB93Q53814000-3848BA61-16D9-4559-A034-8639D607E6E2Q55273917-591E3838-5F4D-4343-9146-86897F690273
P2860
Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies.
@en
type
label
Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies.
@en
prefLabel
Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies.
@en
P2860
P356
P1476
Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies
@en
P2093
Susan R Rheingold
P2860
P356
10.3389/FONC.2014.00108
P577
2014-05-16T00:00:00Z